Thrombosis Update最新文献

{"title":"Bleeding and venous thromboembolism events in cancer patients taking direct oral anticoagulants vs. low molecular weight heparin","authors":"Frank A. Lattuca,&nbsp;Jeremiah Moore,&nbsp;Carissa Treptow,&nbsp;Kendra Delibert,&nbsp;Andrea Baran,&nbsp;Frank Akwaa","doi":"10.1016/j.tru.2022.100129","DOIUrl":"10.1016/j.tru.2022.100129","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with cancer have an increased risk of developing venous thromboembolism (VTE), and subsequently a higher risk of bleeding secondary to anticoagulants. Low-molecular weight heparin (LMWH) has been the standard of care for these patients, with emerging data on the use of direct oral anticoagulants (DOACs). The primary objective of the study was to determine the prevalence of major bleeding events in cancer patients taking DOACs or LMWH for VTE. Secondary objectives included the rate of first VTE recurrence and the effect of concomitant antiplatelet agents and/or significant drug interactions on major bleeding or recurrent VTE.</p></div><div><h3>Materials and methods</h3><p>Using the electronic medical record at the University of Rochester Medical Center, we retrospectively identified adult patients with active malignancy who had a diagnosis of VTE requiring therapeutic anticoagulation within the study period of July 1st, 2015 to June 1st, 2019. Patients were excluded if they were receiving prophylactic doses of LMWH per the institution VTE guidelines. Data on anticoagulant medications were collected as well as information on major bleeding and recurrent VTE events.</p></div><div><h3>Results and conclusions</h3><p>There is insufficient evidence of difference in risk of major bleeding among patients who received a DOAC vs LMWH (cause-specific hazard ratio (HR) = 0.77, 95% CI 0.29–2.04, P = 0.60). There was also no evidence of a difference in risk of recurrent VTE between patients who received DOAC vs. LMWH (cause-specific HR = 0.98, 95% CI 0.15–6.26, P = 0.98). These results suggest that DOACs are not significantly less safe than LMWH for patients with cancer.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"10 ","pages":"Article 100129"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46046028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing anticoagulation stewardship: A call to action for stewardship from the US-based anticoagulation forum","authors":"Allison Burnett ,&nbsp;Kelly M. Rudd ,&nbsp;Darren Triller","doi":"10.1016/j.tru.2022.100125","DOIUrl":"10.1016/j.tru.2022.100125","url":null,"abstract":"<div><h3>Purpose</h3><p>Anticoagulation Stewardship is urgently needed to improve anticoagulation management and bend the current, negative trajectory on anticoagulation-related harm. This manuscript catalogs the origins and the progression of the Anticoagulation Stewardship model and serves as a call to action for healthcare providers and organizations committed to improving the quality and safety of anticoagulation management.</p></div><div><h3>Key elements</h3><p>Tens of millions of patients around the world currently require anticoagulant therapy to prevent or treat thrombotic events. Concerningly, there is a growing body of evidence confirming that increasing volume and complexity of anticoagulant use is significantly impacting the therapeutic landscape, posing major challenges to safe prescribing and management of these high-risk, yet essential therapies, and leading to increased patient harm including life-threatening bleeding and thrombotic complications across the continuum of care. In response, anticoagulation stewardship programs, modeled after highly successful antimicrobial stewardship efforts, are gaining increased traction to counteract this growing health concern.</p></div><div><h3>Conclusions</h3><p>The current health care system is inadequate to protect patients from avoidable harms and to maximize the benefits of therapy. Apart from anticoagulation stewardship, there does not currently exist another cross-setting, multidisciplinary model for achieving maximum quality and safety for patients. If we are to collectively meet the challenge that stands before us, we must commit ourselves (as individuals and organizations) to leveraging the available resources to advance the anticoagulation stewardship model while also contributing to the burden of evidence and the effective articulation of the stewardship message.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100125"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000293/pdfft?md5=3174b515a737686e708c352eecfb63dc&pid=1-s2.0-S2666572722000293-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43156452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ADAMTS13 levels in a plasma-derived FVIII concentrate: A potential therapeutic option for patients with congenital thrombotic thrombocytopenic purpura","authors":"Filippo Mori ,&nbsp;Ilaria Nardini ,&nbsp;Silvia Nannizzi ,&nbsp;Roberto Crea ,&nbsp;Prasad Mathew ,&nbsp;Nicole Ziliotto ,&nbsp;Alessandro Gringeri","doi":"10.1016/j.tru.2022.100120","DOIUrl":"10.1016/j.tru.2022.100120","url":null,"abstract":"<div><h3>Introduction</h3><p>Treatment of congenital thrombotic thrombocytopenic purpura (cTTP), a disease characterized by the congenital deficiency of ADAMTS13, remains a challenge as there are no specific treatments available yet, other than therapy based on the use of fresh frozen plasma (FFP). Since cTTP is caused by low levels of ADAMTS13 protein, commercially available coagulation factor concentrates have been considered as potential ADAMTS13 source in place of FFP. The study aimed to validate the therapeutic potential of a plasma-derived factor VIII (FVIII) product as a source of ADAMTS13.</p></div><div><h3>Methods</h3><p>The quantitation of ADAMTS13 activity levels in eight lots of a plasma-derived FVIII product, (Koāte®) was carried out with three different methodologies: a Fluorescence Resonance Energy Transfer (FRET) assay, a chemiluminescence assay, and a chromogenic ELISA. ADAMTS13 protein antigen levels were measured by the FRET technique as well. In addition, von Willebrand factor (VWF) activity (VWF ristocetin cofactor, VWF:RCo, and VWF collagen binding, VWF:CB) and antigen (VWF:Ag) were measured using chemiluminescence assays. Qualification protocols were applied to the methods used.</p></div><div><h3>Results</h3><p>The results showed high levels of ADAMTS13 in all eight Koāte® lots analyzed, with antigen and activity levels respectively of 10.72 IU/ml ± 3.94 and 5.62 IU/ml ± 1.39. Despite the significant content of ADAMTS13, VWF integrity seems not to be affected (0.81 ± 0.15 VWF:RCo/VWF:Ag and 0.75 ± 0.15 VWF:CB/VWF:Ag ratios).</p></div><div><h3>Conclusions</h3><p>These findings suggest that Koāte® could be a potential candidate for the treatment of cTTP, warranting evaluation in a clinical trial.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100120"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000244/pdfft?md5=49d22146b740dfdea8475cc368e91e07&pid=1-s2.0-S2666572722000244-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41538252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rate and risk factors for thromboembolism and major bleeding in adults with congenital heart disease taking vitamin K antagonist therapy","authors":"Daniel Samarai ,&nbsp;Sandra Lindstedt ,&nbsp;Nazim Isma ,&nbsp;Joanna Hlebowicz","doi":"10.1016/j.tru.2022.100122","DOIUrl":"10.1016/j.tru.2022.100122","url":null,"abstract":"<div><h3>Background</h3><p>The risk of adults with a congenital heart defect (ACHD) developing heart failure, stroke, arrhythmias, and the need for valve replacement is increased compared to healthy peers. Evidence for the use of novel oral anticoagulants (NOAC) in this patient group is still lacking and vitamin K antagonists (VKA) are the primary choice for patients with a mechanical valve. The present aim was to determine the rate of thromboembolic and major bleeding events in ACHD patients on VKA therapy.</p></div><div><h3>Methods</h3><p>This was a retrospective study on ACHD patients on VKA treatment registered in the National Quality Registry for Congenital Heart Disease, SWEDCON, and Atrial fibrillation and Anticoagulation, AuriculA, from Southern Sweden.</p></div><div><h3>Results</h3><p>213 patients were included with a mean age of 50 years (±18) years and a mean follow-up of 6.6 years (±3.3 years), 16% had complex defects and 41% had valvular VKA therapy indication. In total, 34 complications were registered, of which 14 were thromboembolic events and 20 were major bleeding events. The rate of thromboembolism and major bleeding events was 1.0 (95% CI: 0.6–1.6) and 1.4 (95% CI: 0.9–2.2) per 100 patient-years, respectively. Forty-three patients died during the study period. The mortality rate was 3.1 per 100 patient-years (95% CI: 2.2–4.1).</p></div><div><h3>Conclusion</h3><p>We found a low rate of thromboembolic events and major bleeding events for low-moderate risk ACHD patients with good quality of VKA anticoagulation. The target of TTR&gt;65% for ACHD patients is recommended.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100122"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000268/pdfft?md5=ab964f58c1ef523511f12c7b455dd658&pid=1-s2.0-S2666572722000268-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47868518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features, coagulation and inflammatory biomarkers associated with poor in-hospital outcomes in a Honduran population with RT-PCR confirmed COVID-19","authors":"David Aguilar-Andino ,&nbsp;Andrea N. Umaña ,&nbsp;César Alas-Pineda ,&nbsp;Freddy Medina Santos ,&nbsp;Alejandro Cárcamo Gómez ,&nbsp;Marco Molina Soto ,&nbsp;Ana Liliam Osorio","doi":"10.1016/j.tru.2022.100124","DOIUrl":"10.1016/j.tru.2022.100124","url":null,"abstract":"<div><h3>Background</h3><p>SARS-COV-2, in most cases, only generates a mild acute respiratory disease. However, patients with severe disease show an exaggerated response of the immune system, creating a pro-inflammatory state, which could cause abnormalities in the coagulation system that increases mortality. Latin American countries, specially those with limited resources, have few studies about clinical features, coagulation and inflammatory biomarkers that could be useful at admission to assess poor outcomes.</p></div><div><h3>Objective</h3><p>The objective of this study is to describe the clinical features, coagulation, and inflammatory biomarkers, and identify risk factors at admission that are associated poor outcomes in Honduran population.</p></div><div><h3>Methods</h3><p>A cohort study was conducted. 210 patients were included, which 105 died during hospitalization due to COVID-19 and 105 were discharged alive, between September 2020 and January 2021. Clinical and laboratorial data was retrospectively collected.</p></div><div><h3>Results</h3><p>57,6% of the population were male. The median age was 58 years. The median time between symptom onset and hospital admission was 6 days. D-dimer median was higher in the dead group compared with the alive group. Poor prognosis factors in the Cox multivariable model were male gender, age, symptom's duration, obesity and an elevated d dimer at admission.</p></div><div><h3>Conclusion</h3><p>In low-middle income countries, the assessment of these clinical and laboratory tools, especially in those with risk factors for prothrombotic states, could help clinicians to correctly stratify disease prognosis, establish a baseline to evaluate further evolution, and also predict outcomes, thus improving patient management.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100124"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000281/pdfft?md5=9150f9dcfa9bf43ea011462851bac35d&pid=1-s2.0-S2666572722000281-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47007013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective real-world meta-analysis of high-risk major bleeding as a primary safety outcome in cancer patients receiving therapeutic anticoagulation","authors":"Ritika Halder ,&nbsp;Eric Brucks ,&nbsp;Ce Cheng ,&nbsp;Kathylynn Saboda ,&nbsp;Hani M. Babiker ,&nbsp;Ali Mcbride ,&nbsp;Alejandro Recio-Boiles","doi":"10.1016/j.tru.2022.100121","DOIUrl":"10.1016/j.tru.2022.100121","url":null,"abstract":"","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100121"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000256/pdfft?md5=90aef91be499c69d2c6f17b6df9fd052&pid=1-s2.0-S2666572722000256-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41720442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour-associated Mucin1 correlates with the procoagulant properties of cancer cells of epithelial origin","authors":"Yunliang Chen,&nbsp;Michael Scully","doi":"10.1016/j.tru.2022.100123","DOIUrl":"10.1016/j.tru.2022.100123","url":null,"abstract":"<div><h3>Background</h3><p>Cancer-associated thrombosis (CAT) is caused, at least in part, by procoagulant factors produced by the tumour itself<strong>.</strong> Although MUC1 is an established biomarker for the diagnosis, immunotherapy, and prognosis of cancer, it is unclear whether it contributes to the procoagulant phenotype of cancer cells.</p></div><div><h3>Methods</h3><p>MUC1 knockdown breast cancer MCF-7 cells were used to investigate the influence of overexpression of MUC1 on procoagulant parameters. In addition, the effect of treating normal human epithelial cells with extracellular vesicles from several human breast and pancreatic cancer cell lines, which overexpress MUC1, was determined. The impact of a pharmacological anti-MUC1 antibody on cancer cells was also analysed.</p></div><div><h3>Results</h3><p>The level of a range of procoagulant proteins was observed to correlate with the MUC1 level of human breast and pancreatic cancer cell lines. MUC1 downregulation in MCF-7 cells led to a reduction in the procoagulant parameters particularly thrombin activity. The levels of selected tumorigenic markers, procoagulant proteins and miRNAs associated with tumorigenicity and thromboembolism were also modulated by treatment of normal cells with tumour cell derived extracellular vesicles in correlation with that of the extracellular vesicles donor cells. Moreover, the procoagulant properties were also reduced by an anti-MUC1 antibody in these cancer cells.</p></div><div><h3>Conclusions</h3><p>A range of procoagulant proteins found in human breast and pancreatic cancer cells were shown to exhibit a positive correlation with the level of MUC1 and thereby potentially contribute to the pathogenesis of CAT. The reduction of the procoagulant activity by MUC1 antibody could be an additional beneficial effect of its therapeutic efficacy. These findings also suggest that the level of tumour associated MUC1 could be of use as a risk factor for CAT.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100123"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266657272200027X/pdfft?md5=de5d948d777adca91710baebd10336e6&pid=1-s2.0-S266657272200027X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46368437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of extended treatment with direct oral anticoagulants for venous thromboembolism in Japan: A retrospective cohort study using claims data","authors":"Hiroyuki Hashimoto,&nbsp;Shinobu Imai,&nbsp;Anna Kiyomi,&nbsp;Munetoshi Sugiura","doi":"10.1016/j.tru.2022.100113","DOIUrl":"10.1016/j.tru.2022.100113","url":null,"abstract":"<div><h3>Purpose</h3><p>We aimed to evaluate the risk of recurrent venous thromboembolism (VTE) among patients receiving direct oral anticoagulant (DOAC) therapy (extended and non-extended) using claims data.</p></div><div><h3>Methods</h3><p>Patients treated with DOACs at the first VTE event were identified using Japanese claims data; Cox proportional hazard models were used to evaluate the risk of recurrence. Unadjusted, adjusted, and stabilized inverse probability treatment weighting (s-IPTW) analyses were used to assess the differences between patients treated for more than 90 days after the index date (extended treatment group) and those treated within 90 days (nonextended treatment group). Bleeding was assessed separately from recurrent VTE evaluation during the observation period.</p></div><div><h3>Results</h3><p>We included 4,010 patients (mean age, 69 years; 57.9% females; extended: 2,684, nonextended: 1,326). After IPTW, all patient characteristics were well balanced. When the follow-up was censored at 18 months, the hazard ratio (extended/nonextended) for unadjusted, adjusted, and two s-IPTW analyses were 1.31 (P = 0.2762), 1.25 (P = 0.372), 1.32 (P = 0.2579), and 1.33 (P = 0.2498), respectively. The proportions of those who experienced intracranial, gastrointestinal, respiratory, and renal/urinary tract bleeding during the observation period in both groups were 2.9% vs. 3.8%, 2.1% vs. 2.3%, 1.0% vs. 0.5%, and 1.4% vs. 0.7% (extended vs. nonextended), respectively.</p></div><div><h3>Conclusions</h3><p>There were no differences in VTE recurrence between the two groups. In clinical practice and with a risk-benefit evaluation, both VTE treatment types were well controlled. Further evaluation is required, considering patient background within the observation period of 90 days and safety of treatment for bleeding events.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"8 ","pages":"Article 100113"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000177/pdfft?md5=91fb5bb1ed4869b1b52000018248b476&pid=1-s2.0-S2666572722000177-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48701396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial presentation of Systemic Lupus Erythematosus coinciding with Thrombotic Thrombocytopenic Purpura","authors":"Dariusz Uczkowski,&nbsp;Hristos Milonas","doi":"10.1016/j.tru.2022.100118","DOIUrl":"10.1016/j.tru.2022.100118","url":null,"abstract":"<div><p>Thrombotic Thrombocytopenic Purpura (TTP) is a rare form of thrombotic microangiopathy (TMA) typically characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and end-organ ischemia secondary to microvascular dissemination of platelet-rich thrombi. Systemic Lupus Erythematosus (SLE) is a chronic autoimmune condition characterized by multi-organ system inflammation with the generation of autoantibodies. The specific cause of SLE is unknown but multiple factors seem to be associated with the development of the disease including: genetic, epigenetic, ethnic, hormonal, and environmental factors. In SLE, patients may present with a wide assortment of clinical variations, but diagnosis is based generally on clinical and laboratory findings after excluding alternative diagnoses. Very rarely do SLE and TTP present simultaneously. Both disease processes have overlapping clinical features which makes diagnosis and management challenging. The following case report describes a forty-year-old female with no prior history of SLE or TTP who presented with clinical findings and features of TTP as the initial clinical manifestation of her underlying SLE, as well as serologic criteria, requiring treatment with plasma exchange, high dose steroids, and eventual outpatient infusion with Rituximab.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"8 ","pages":"Article 100118"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000220/pdfft?md5=3fca701b86939e415d434aa8f94e5f33&pid=1-s2.0-S2666572722000220-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41647426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The mechanistic basis linking cytokine storm to thrombosis in COVID-19","authors":"Adam Wolf ,&nbsp;Faria Khimani ,&nbsp;Braian Yoon ,&nbsp;Coltin Gerhart ,&nbsp;Dakota Endsley ,&nbsp;Anish K. Ray ,&nbsp;Angelito F. Yango ,&nbsp;Stuart D. Flynn ,&nbsp;Gregory Y.H. Lip ,&nbsp;Stevan A. Gonzalez ,&nbsp;Mohanakrishnan Sathyamoorthy","doi":"10.1016/j.tru.2022.100110","DOIUrl":"10.1016/j.tru.2022.100110","url":null,"abstract":"<div><p>It is now well established that infection with SARS-CoV-2 resulting in COVID-19 disease includes a severely symptomatic subset of patients in whom an aggressive and/or dysregulated host immune response leads to cytokine storm syndrome (CSS) that may be further complicated by thrombotic events, contributing to the severe morbidity and mortality observed in COVID-19. This review provides a brief overview of cytokine storm in COVID-19, and then presents a mechanistic discussion of how cytokine storm affects integrated pathways in thrombosis involving the endothelium, platelets, the coagulation cascade, eicosanoids, auto-antibody mediated thrombosis, and the fibrinolytic system.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"8 ","pages":"Article 100110"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000141/pdfft?md5=fc880466db41b5ce8f74e5a2b50225e4&pid=1-s2.0-S2666572722000141-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46581161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}